Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus

As Immuno-Inflammation Pipeline Advances

02 Mar 2023

• By Ayisha Sharma

The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.

Yellow refresh symbol arrows on orange background — Servier Is Entering A New Era Of Neuroscience R&D • Source: Shutterstock

Les Laboratoires Servier is on a mission to add some spark to its neuroscience pipeline by developing RNA-targeting drugs for neurodegenerative conditions as it tries to follow in the footsteps of the likes of Biogen, Inc.’s Spinraza. Elsewhere, the company believes its immuno-inflammation pipeline could yield a new monoclonal antibody product for Sjörgen’s syndrome.

The French firm has a track record of developing and marketing novel neuroscience drugs including in the psychiatry space. Back...